India’s Glenmark launches COVID-19 drug at $1.35 per tablet.

Indian drug firm Glenmark Pharmaceuticals has launched anti-viral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 at a price of about Rs 103 ($1.35) per tablet.According to the largest news agency in India, PTI, the drug will be available as a 200mg tablet at a maximum retail price of Rs 3,500 ($45.88) for a strip of 34 tablets.FabiFlu is the first oral medication that has been approved in India for the treatment of COVID-19, it added.

It is a prescription-based medication, with recommended dose being 1,800mg twice daily on day one, followed by 800mg twice daily up to day 14, the drug firm said.”Considering a minimum of two strips per patient, Glenmark will be able to provide FabiFlu for about 82,500 patients in the first month itself. We will be closely monitoring the evolving situation and on [the] basis [of] the situation, we will work to scale and meet the healthcare needs of the country,” Glenmark told PTI when asked about the company’s manufacturing capacity of the drug, the firm said.

The Mumbai-based firm received the manufacturing and marketing approval from the Drugs Controller General of India on Friday. The tablets are being produced by the company at its Baddi facility in the northern Indian state of Himachal Pradesh. The drug will be available both through hospitals and the retail channel, Glenmark said.According to the company, FabiFlu will considerably help assuage this pressure and offer patients in India a much needed and timely therapy option, he added.

“Glenmark will work closely with the government and medical community to make FabiFlu quickly accessible to patients across the country,” Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said in a statement.

The company has successfully developed the active pharmaceutical ingredient and the formulation for FabiFlu through its in-house research and development team, PTI reported .

Source: Zawya

No.of Reads (17)


A light Year Ahead News Source.